Compounder Definition In House Bill May Use Blended Metrics
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA and stakeholders reiterate that volume cannot be the sole measure of whether a compounder should be regulated like a drug manufacturer; Rep. Griffith pitches potentially using it and other indicators to draw the line.
You may also be interested in...
Compounding Bill In Senate Gets Bipartisan Push For Floor Vote
HELP Committee leaders Harkin and Alexander write letter arguing that FDA’s warnings of more problems from tainted compounded medications have come true and that their legislation should gain a vote next month.
Pfizer COVID-19 Vaccine Trial Diversity Slips As Enrollment Rises, Unlike Moderna
Trial diversity is among the issues that stakeholders worry could hinder vaccine uptake.
Pink Sheet Podcast: COVID-19 Stresses Manufacturing, Vaccine Placebo Controls, Thorny FDA Precedents
Pink Sheet reporters and editor discuss the pandemic’s effects on non-coronavirus-related product manufacturing, US FDA efforts to ensure vaccine sponsors maintain placebo controls once a product is available, and precedents that burden the agency.
Need a specific report? 1000+ reports available Buy Reports
Register for our free email digests: